Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,734 active trials43 approved drugs557 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,061 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07403136 | Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC | recruiting | Phase 2 | 104 | Fudan UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07676461 | Oral, Fecal and Intratumoral Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line Immunotherapy(ATLAS) | recruiting | — | 150 | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloOTHER | 1 |
| Jul 7, 2026 |
| clinicaltrials |
| NCT04184973 | Efficacy and Safety of the CG-100 Intraluminal Bypass Device | recruiting | N/A | 250 | Colospan Ltd.INDUSTRY | 5 | Jul 6, 2026 | clinicaltrials |
| NCT04389632 | A Study of Sigvotatug Vedotin in Advanced Solid Tumors | recruiting | Phase 1 | 1,006 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 6, 2026 | clinicaltrials |
| NCT04634357 | ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma(ARYA-2) | recruiting | Phase 1 / Phase 2 | 12 | Eureka Therapeutics Inc.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06435260 | Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer | recruiting | Phase 2 | 30 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 112 | Perspective TherapeuticsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07243015 | Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers(DESTINEX-REM) | recruiting | — | 500 | City of Hope Medical CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07276529 | Initial Safety of SFM Plus OTOLoc for Creating Side-to-side or End-to-side Colorectal Anastomoses(Colonic) | recruiting | N/A | 30 | GI Windows, Inc.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07300150 | A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors | recruiting | Phase 1 | 210 | PAQ Therapeutics, Inc.INDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT07481383 | A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer | recruiting | Phase 1 | 12 | Continuity Biosciences, LLCINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07635316 | A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients | recruiting | — | 4,023 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683845 | Patient-Derived Organoid-on-a-Chip Model for Personalized Prediction of Chemotherapy Efficacy in Pancreatic Cancer | recruiting | — | 164 | Beijing Daxiang Biotech Co., LtdINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05183126 | Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | recruiting | Phase 4 | 22 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06101277 | Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)(LIVELONG) | recruiting | N/A | 300 | University of California, DavisOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06184152 | CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules | recruiting | N/A | 600 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06260943 | Targeted Navigation in Hepatocellular Carcinoma (HCC) | recruiting | N/A | 210 | University of MiamiOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07169734 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Alentis Therapeutics AGINDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07561814 | A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data | recruiting | — | 1,030 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04472767 | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | recruiting | Phase 2 | 35 | University of California, IrvineOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04643366 | Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer | recruiting | Phase 2 | 64 | Virginia Commonwealth UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05530343 | Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance(SWAT-BE) | recruiting | N/A | 2,298 | University of Colorado, DenverOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06364384 | Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma | recruiting | Phase 2 | 20 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06630130 | Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer | recruiting | Phase 2 | 100 | Jeeyun LeeOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07022015 | Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy(POPF) | recruiting | N/A | 100 | Minia UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07186296 | EXoPERT EMERALD Clinical Study | recruiting | — | 1,400 | EXoPERTINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07265271 | Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)(CENTINEL) | recruiting | — | 600 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07549399 | SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC(CRITⅡ) | recruiting | Phase 3 | 204 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07595874 | Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3(NEST3) | recruiting | Phase 2 | 100 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07679061 | First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE) | recruiting | — | 200 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03051464 | Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery(MORPHEUS) | recruiting | Phase 2 / Phase 3 | 131 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 2 | Jun 30, 2026 | clinicaltrials |
| NCT05013216 | Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer | recruiting | Phase 1 | 37 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05323409 | Improving Comprehensive Care of Cancer Patients | recruiting | N/A | 340 | Baylor College of MedicineOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06098560 | Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients | recruiting | — | 60 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06794086 | SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases(SPARKLE-L) | recruiting | Phase 3 | 24 | Jun HuangOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07056777 | Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer | recruiting | Phase 1 / Phase 2 | 186 | Zhejiang Doer Biologics Co., Ltd.INDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07675967 | Clonal Hematopoiesis Chemotherapy and Radiation Effects Study(CH CARE) | recruiting | — | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05276791 | EMR Versus ESD for Barrett's Neoplasia(REMOVE-RCT) | recruiting | N/A | 331 | St. Antonius HospitalOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05516628 | Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma(EMPHASIS) | recruiting | Phase 2 | 30 | National Cancer Centre, SingaporeOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06714318 | SMARTER: Using Blood Samples to iMprove FIT-bAsed coloRecTal cancEr scReening | recruiting | — | 1,000 | Vejle HospitalOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06747585 | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | Alentis Therapeutics AGINDUSTRY | 8 | Jun 29, 2026 | clinicaltrials |
| NCT06780787 | FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery | recruiting | Phase 2 | 26 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06922383 | A Clinical Study of Arfolitixorin in Patients With mCRC | recruiting | Phase 1 / Phase 2 | 90 | Isofol Medical ABINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07327489 | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)(ELEPHAS-05) | recruiting | — | 2,000 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07458347 | A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation | recruiting | Phase 1 | 145 | Kestrel Therapeutics, Inc.OTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07529626 | Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer(MIND-PANC) | recruiting | — | 320 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07587268 | Molecular Profiling for Risk Stratification in Appendiceal Cancer | recruiting | — | 400 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673861 | Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients(CURTAIN) | recruiting | N/A | 100 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 29, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 7, 2026source: clinicaltrials